Harvard Bioscience (NASDAQ:HBIO) Coverage Initiated by Analysts at Zacks Research

Zacks Research assumed coverage on shares of Harvard Bioscience (NASDAQ:HBIO) in a report published on Tuesday,Zacks reports. The brokerage issued a hold rating on the medical instruments supplier’s stock.

HBIO has been the subject of several other reports. Benchmark increased their price objective on Harvard Bioscience from $6.00 to $7.50 and gave the company a “speculative buy” rating in a research report on Wednesday, August 12th. Weiss Ratings lowered shares of Harvard Bioscience from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, August 14th. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Harvard Bioscience presently has a consensus rating of “Hold” and an average price target of $6.75.

Harvard Bioscience Price Performance

NASDAQ HBIO opened at $8.61 on Tuesday. The stock has a 50-day simple moving average of $8.19 and a 200 day simple moving average of $6.47. Harvard Bioscience has a twelve month low of $4.00 and a twelve month high of $9.10. The stock has a market capitalization of $39.18 million, a PE ratio of -3.73 and a beta of 1.47. The company has a debt-to-equity ratio of 4.94, a quick ratio of 0.98 and a current ratio of 1.87.

Harvard Bioscience (NASDAQ:HBIO) last released its earnings results on Tuesday, August 11th. The medical instruments supplier reported ($0.14) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.07. The firm had revenue of $22.73 million for the quarter, compared to analyst estimates of $21.45 million. Harvard Bioscience had a negative return on equity of 33.13% and a negative net margin of 11.86%. Research analysts anticipate that Harvard Bioscience will post -2.44 EPS for the current year.

Institutional Investors Weigh In On Harvard Bioscience

An institutional investor recently bought a new stake in Harvard Bioscience stock. Meros Investment Management LP purchased a new stake in Harvard Bioscience, Inc. (NASDAQ:HBIO) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 182,992 shares of the medical instruments supplier’s stock, valued at approximately $1,125,401. Meros Investment Management LP owned 4.02% of Harvard Bioscience at the end of the most recent reporting period. 80.87% of the stock is owned by institutional investors.

Key Stories Impacting Harvard Bioscience

Here are the key news stories impacting Harvard Bioscience this week:

• Neutral Sentiment: Sidoti forecasts a gradual improvement, with estimated losses of $2.44 per share in 2026 and $1.15 in 2027, followed by positive EPS of $0.43 in 2028. The outlook suggests a potential longer-term recovery, but the articles do not indicate that these estimates were revisions. MarketBeat Harvard Bioscience coverage
• Neutral Sentiment: CEO John Duke and CFO Mark Frost are scheduled to participate in Canaccord Genuity’s MedTech, Diagnostics, and Digital Health and Services Forum on November 11. No new financial or operating information was disclosed in the announcement. Forum participation announcement

About Harvard Bioscience

Harvard Bioscience, Inc (NASDAQ: HBIO) develops, manufactures and supplies specialized tools, equipment and consumables used in biomedical research, drug discovery and related life science applications. Its products support work in areas such as cell biology, electrophysiology, gene delivery, organ-on-chip research and preclinical studies.

The company’s portfolio includes laboratory instruments, tissue and organ perfusion systems, electrophysiology equipment, cell and molecular biology products, and related consumables.